IDO1 and neoplasm: An example of this approach has been proposed by Sharma et al. who demonstrated that reprograming of mature pre-existing tumor-associated Treg into CD40L-expressing helper effector cells was needed to achieve tumor regression in a model of immunotherapy combining antigen vaccination, TLR-9 stimulation, and IDO blockade (152).